Boston Scientific (BSX) Cash from Financing Activities (2009 - 2026)

Boston Scientific has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$410.0 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities fell 20.59% year-over-year to -$410.0 million; the TTM figure through Jun 2026 stood at -$958.0 million (down 940.35% YoY), while the FY2025 annual figure was -$395.0 million, down 121.78% from the prior year.
• Cash from Financing Activities came in at -$410.0 million for Q2 2026 at Boston Scientific, down from -$260.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.6 billion in Q1 2024 to a low of -$410.0 million in Q2 2026.
• Average Cash from Financing Activities over 5 years is $11.4 million, with a median of -$2.5 million recorded in 2022.
• Year-over-year, Cash from Financing Activities sank 17300.0% in 2022 and jumped 2373.91% in 2024.
• Over 5 years, Cash from Financing Activities stood at $1.0 million in 2022, then soared by 1400.0% to $15.0 million in 2023, then surged by 1326.67% to $214.0 million in 2024, then slumped by 185.98% to -$184.0 million in 2025, then plunged by 122.83% to -$410.0 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were -$410.0 million in Q2 2026, -$260.0 million in Q1 2026, and -$184.0 million in Q4 2025.